Nice_老虎社区_美港股上老虎

2021-12-02

Nice

Novartis Says Top Drugs Should Fuel Sales Growth Through 2026

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603567349,"tweetId":"603567349","gmtCreate":1638429661733,"gmtModify":1638429661852,"author":{"id":3571302905057300,"idStr":"3571302905057300","authorId":3571302905057300,"authorIdStr":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603567349","repostId":1159695915,"repostType":4,"repost":{"id":"1159695915","kind":"news","pubTimestamp":1638429346,"share":"https://www.laohu8.com/m/news/1159695915?lang=&edition=full","pubTime":"2021-12-02 15:15","market":"us","language":"en","title":"Novartis Says Top Drugs Should Fuel Sales Growth Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1159695915","media":"Marketwatch","summary":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it exp","content":"<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.</p>\n<p>The Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.</p>\n<p>\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.</p>\n<p>Novartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Says Top Drugs Should Fuel Sales Growth Through 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Says Top Drugs Should Fuel Sales Growth Through 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 15:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click><strong>Marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while...</p>\n\n<a href=\"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.marketwatch.com/story/novartis-says-top-drugs-should-fuel-sales-growth-through-2026-271638427973?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1159695915","content_text":"Novartis AG said Thursday ahead of its research-and-development day starting later today that it expects sales to keep growing in the mid-term mainly thanks to its main in-market growth drivers, while several new assets could be approved by 2026.\nThe Swiss pharma giant said that sales should continue to rise at a compound annual growth rate of at least 4% through 2026, driven by multi-billion dollar sales from its medicines Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio.\n\"Up to 20 new assets with significant sales potential could be approved by 2026, which will fuel the next phase of growth and address major unmet needs,\" Novartis's Chief Executive Vas Narasimhan said.\nNovartis also said that Cosentyx, its largest drug by sales, met primary efficacy endpoints in two phase 3 studies called Sunrise and Sunshine in which patients are treated for moderate to severe hidradenitis suppurativa--a chronic skin disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":973,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603567349"}